The biotechnology company Bico is launching the Bico 2030 strategy with an increased focus on Precision Biology and at the same time confirms its long-term financial targets.
The Group continues to target double-digit organic growth excluding currency effects, an EBITDA margin after capitalized development costs of above 10 percent, and net debt in relation to EBITDA of below 3.0 times.
New long-term financial targets will be established once the current ones have been achieved.
The new strategy is intended to contribute to improved profitability and increased cash generation. Bico is dropping large-scale integrated lab automation projects as a strategic focus and is evaluating alternatives for Biosero.
As of 11 November, Group management consists of CEO Anders Fogelberg, CFO Ewa Linsäter, Petros Apostolopoulos, Head of Lab Instruments, Avijit Minocha, Head of Cellink, and CTO Julian Riba.
